Funding for this research was provided by:
Astellas Pharma
Article History
Received: 19 January 2021
Accepted: 5 April 2021
First Online: 28 April 2021
Declarations
:
: Yasuo Terauchi has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., Merck Sharp & Dohme K.K., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and has received research donations from AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly Japan K.K., Merck Sharp & Dohme K.K., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., and Takeda Pharmaceutical Co., Ltd. Tetsushi Takada is an employee of Astellas Pharma Inc. Satoshi Yoshida is an employee of Astellas Pharma Inc.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients for being included in the study.
: This research involves human participants. The study protocol was approved by the local ethics committee at each medical institution, the Medical Corporation Toukeikai Kitamachi Clinic Ethical Review Board (approval number AST05921, approved June 28, 2018), or the Joint Ethical Review Board (approval number 14000050.20180817-4654, approved August 17, 2018).
: All patients provided written informed consent before participating.